TLR9 and systemic lupus erythematosus: Despite its original development for acute myeloid leukemia, Oon et al., in 2016, showed that CSL362 could deplete pDC and basophils ex vivo and then inhibit TLR9-induced IFNα production in peripheral blood mononuclear cells (PBMCs) from a cohort of SLE patients [77].